PT-141 compounding pharmacy vs research supplier: what's legal

Last updated 2026-07-24

What is a PT-141 compounding pharmacy?

A compounding pharmacy is a state-licensed facility that prepares medications on a prescription basis, often when FDA-approved products are unavailable, unsuitable, or prohibitively expensive. Bremelanotide (marketed as Vyleesi) is FDA-approved for hypoactive sexual desire disorder in premenopausal women ^[1], but the commercial product costs several hundred dollars per dose and requires autoinjector cartridges. Compounding pharmacies can prepare bremelanotide injections from bulk active pharmaceutical ingredients (APIs) if the bulk substance appears on the FDA's 503A or 503B lists ^[2]. As of mid-2025, bremelanotide does not appear on the current 503A bulks list ^[3], which means traditional pharmacy compounders cannot legally use it unless they meet narrow office-use or patient-specific criteria under state law. The 503B list (for outsourcing facilities) is separate and periodically updated ^[4]. A legitimate compounding pharmacy requires a prescription from a licensed provider. It will ship only to the patient named on the script, often after verifying the prescription with the prescriber. The pharmacy operates under state boards of pharmacy, undergoes regular inspections, and must follow USP 797 sterility standards for injectable medications. You'll see a pharmacy license number, a physical address, and a responsible pharmacist listed on every order. Compounding pharmacies that work with telemedicine providers often handle fulfillment after a virtual consultation and prescription. Bremelanotide Rx connects patients to licensed clinicians who review eligibility and, if appropriate, write a prescription fulfilled by a partner pharmacy registered with state and federal authorities.

What is a research supplier?

Research suppliers sell chemical compounds labeled 'for research purposes only' or 'not for human use'. These vendors market peptides, SARMs, and other molecules to individuals who intend to self-administer them, though the label provides legal cover. Research suppliers are not pharmacies. They are not licensed to dispense medications, they do not require prescriptions, and they have no obligation to verify purity, sterility, or identity beyond what they choose to disclose. Many research suppliers provide certificates of analysis (COAs) from third-party labs showing peptide purity by HPLC. These COAs confirm that the powder in the vial matches the expected molecular weight and is 95 or 98 percent pure by mass. They do not confirm sterility, endotoxin levels, or the absence of heavy metals or solvent residues. They do not test the final reconstituted solution you inject. And the COA itself is voluntary; no regulator audits the process or punishes discrepancies. Research suppliers typically ship lyophilized powder with bacteriostatic water or sterile water for injection. The buyer reconstitutes the peptide at home and draws up doses with insulin syringes. Packaging is discreet. Payment is often by cryptocurrency, Zelle, or wire transfer because credit card processors classify these transactions as high-risk. Customer service is minimal, returns are rare, and there is no pharmacovigilance reporting if something goes wrong. Using a research chemical for self-treatment is illegal under the Federal Food, Drug, and Cosmetic Act ^[5]. The moment you inject a substance labeled 'not for human use', you violate the intended-use doctrine codified in 21 CFR 201.128 ^[6]. Customs and Border Protection can seize international shipments, and state medical boards can discipline providers who recommend research chemicals to patients.

Is bremelanotide legal to compound in the United States?

Bremelanotide's legality in compounding depends on which bulk-substance list applies. Under the Drug Quality and Security Act (DQSA), a pharmacy compounder operating under 21 U.S.C. 353a may compound a drug only if the API appears on the 503A bulks list or meets narrow criteria for nomination ^[7]. The current 503A list, last updated in July 2022, does not include bremelanotide ^[3]. Outsourcing facilities (503B) have a separate list of bulk substances and more flexibility ^[4]. Some 503B facilities compound bremelanotide under that pathway, but they must register with FDA, pass biennial inspections, report adverse events, and label products with beyond-use dates and lot numbers. These are not corner pharmacies; they are small-scale manufacturers subject to current good manufacturing practice (cGMP). Some compounding pharmacies argue that bremelanotide is a nominated substance or that state law permits office-use compounding outside federal lists. The FDA's nomination database shows bremelanotide was nominated by at least one party ^[8], but nomination does not equal approval. Until FDA formally adds a substance to the bulks list and publishes it in the Federal Register, it is not available for routine 503A compounding. State boards vary in how they interpret the gap between federal and state authority, so you'll find bremelanotide compounding happening in certain states while others shut it down. For a patient, the safe assumption is this: if a pharmacy will fill a bremelanotide prescription, ask for its DEA number, state license, and 503B registration (if applicable). If it can't provide those, it's not operating as a pharmacy.

What are the risks of buying PT-141 from a research supplier?

The largest risk is product uncertainty. Research suppliers have no legal obligation to provide sterile, endotoxin-free, or accurately dosed peptides. A 2021 analysis of consumer peptides purchased online found significant variance in labeled versus actual content, with some vials containing less than 50 percent of the claimed peptide. Even when purity is high, sterility is a separate issue. Lyophilized powder may be free of bacteria, but once you reconstitute it with bacteriostatic water and store it in your refrigerator, contamination can occur. Home users rarely follow aseptic technique or use sterile gloves, alcohol swabs, and laminar flow hoods. Injection-site infections, abscesses, and systemic sepsis have all been reported in communities that use research peptides, though published case series are sparse because patients rarely disclose the source. Endotoxin contamination (lipopolysaccharide from gram-negative bacteria) can cause fever, chills, and hypotension even when live bacteria are absent. HPLC purity does not measure endotoxin; that requires a separate LAL (limulus ameboid lysate) assay, which research suppliers do not routinely perform. Dosing is another problem. Bremelanotide's approved dose is 1.75 mg subcutaneously, delivered via a prefilled autoinjector ^[1]. Research suppliers sell 10 mg vials, which you reconstitute with 2 mL of water to yield 5 mg/mL. Drawing 0.35 mL gives you 1.75 mg, but insulin syringes have 0.01 mL gradations, so dosing error is easy. Overdosing bremelanotide increases nausea, flushing, and transient hypertension; underdosing leaves you with no effect and wasted money. Legal risk is real. Importing scheduled or unapproved drugs is a felony under the FDCA ^[5]. Most research peptides are not scheduled under the Controlled Substances Act, so you won't face DEA prosecution, but Customs can seize the package and send you a notice of seizure. Repeated orders can trigger further scrutiny. Some buyers face state-level charges if local prosecutors decide to pursue distribution or possession of unapproved drugs, though this is rare for personal-use quantities. Finally, there is no recourse. If the peptide doesn't work, if you have an allergic reaction, or if you develop an infection, you cannot sue a research supplier. Their terms of service disclaim all liability, and you agreed to them by purchasing. You also cannot file an adverse event report with FDA MedWatch, because MedWatch is for FDA-regulated products. You're on your own. For more on sourcing traps, see best place to buy PT-141 and PT-141 peptide for sale on Amazon.

How does a prescription compounding pharmacy ensure safety?

A licensed compounding pharmacy follows United States Pharmacopeia chapter 797, which sets sterility standards for compounded sterile preparations (CSPs). USP 797 requires clean rooms with HEPA filtration, regular air-quality testing, media-fill validation (simulating sterile compounding with nutrient broth to detect contamination), and personnel gowning protocols. Pharmacies must document every step, from receipt of the bulk API to final dispensing, with lot numbers and beyond-use dates on every label. Pharmacies source active pharmaceutical ingredients from FDA-registered suppliers, often through distributors that provide certificates of analysis and stability data. The API is tested again on receipt or periodically by the pharmacy's quality control process. Injectable solutions are filtered through 0.2-micron filters to remove bacteria, and endotoxin testing is performed on high-risk batches. The final product is labeled with the patient's name, the prescriber's name, the compounding date, the beyond-use date, storage instructions, and the pharmacy's contact information. Every compounding pharmacy has a responsible pharmacist who reviews each prescription for interactions, contraindications, and dosing errors. If you're taking antihypertensives, for example, the pharmacist may flag that bremelanotide causes transient blood pressure elevation and recommend monitoring. If your prescribed dose is outside the studied range, the pharmacist will contact the prescriber for clarification. This oversight doesn't exist with research suppliers. Pharmacies also report adverse events. If you call with nausea, rash, or injection-site pain, the pharmacist documents it and, if serious, files a MedWatch report with FDA. This post-market surveillance improves safety for everyone. Research suppliers have no such feedback loop. State boards of pharmacy inspect compounding facilities annually or biennially, reviewing records, observing compounding technique, and testing environmental samples. Violations trigger corrective action plans, fines, or license suspension. The threat of inspection keeps standards high. Research suppliers face no equivalent oversight.

What does bremelanotide compounding cost?

Compounded bremelanotide from a 503B outsourcing facility or a state-licensed pharmacy operating within legal bounds typically costs $50 to $150 per dose, depending on whether you buy single vials or multi-dose kits. A 10 mg vial reconstituted at home yields roughly five to six 1.75 mg doses, so per-dose cost can drop to $15 to $30 if you're comfortable with self-reconstitution and multi-dose vial storage. The FDA-approved Vyleesi autoinjector costs $800 to $1,000 per dose without insurance ^[1]. Insurance rarely covers it because hypoactive sexual desire disorder is not universally recognized as a reimbursable diagnosis, and many plans classify sexual-function drugs as lifestyle exclusions. That price gap is why compounding exists. Research suppliers charge $40 to $80 for a 10 mg vial of 'PT-141' or 'bremelanotide (research grade)', plus $10 to $20 for bacteriostatic water and syringes. Shipping is $5 to $15 domestic, or free over a certain order threshold. Total cost for a six-dose supply is $50 to $100. The price is lower because there is no pharmacy overhead, no compliance cost, and no pharmacist review. You're paying for bulk chemical and packaging, not a regulated medication. If you go the compounding route through a telemedicine provider like Bremelanotide Rx, you'll pay a consultation fee (typically $50 to $100) and the pharmacy fulfillment cost. The total upfront is $100 to $250, which includes the provider evaluation, prescription, and first fill. Refills are cheaper because you skip the consultation. This is still far below Vyleesi's price and avoids the legal and safety unknowns of research supply.

Can a doctor prescribe compounded PT-141 legally?

A physician, nurse practitioner, or physician assistant licensed in your state can write a prescription for compounded bremelanotide if they determine it's medically appropriate and the compounding pharmacy can legally fill it. The prescriber must document a legitimate patient-practitioner relationship, which usually means a history, examination (even if virtual), and a diagnosis. Hypoactive sexual desire disorder, low libido, or arousal difficulty are the typical indications. The prescriber does not decide whether the pharmacy can compound it. That's a pharmacy law question. If the pharmacy says it can fill the script under 503B or a state-specific compounding exemption, the prescriber can proceed. If the pharmacy says bremelanotide is not on the bulks list and cannot be compounded, the prescriber cannot force the issue by writing a prescription anyway. Some prescribers write for 'bremelanotide 1.75 mg subcutaneous injection' and leave sourcing to the patient, assuming the patient will use a research supplier. That's ethically and legally questionable. The prescriber has a duty to ensure the patient receives a safe, legal product. Directing a patient to a research chemical is tantamount to endorsing an unapproved drug, which can trigger medical board discipline and malpractice exposure if the patient is harmed. Reputable telemedicine platforms screen compounding pharmacies before partnering with them, verifying licenses, inspection records, and bulk-substance compliance. The platform's prescribers then write prescriptions only if the partner pharmacy confirms it can compound the medication legally. This closed-loop model protects both patient and prescriber. For more on the provider-reviewed pathway, see PT-141 peptide therapy near me.

What should I ask a compounding pharmacy before ordering?

Start with licensure. Ask for the pharmacy's state license number and verify it with the state board of pharmacy's online lookup tool. Every state board publishes a searchable database of active pharmacy licenses. If the 'pharmacy' cannot provide a license number, it's not a pharmacy. Ask whether the pharmacy operates under 503A or 503B. A 503A compounder fills patient-specific prescriptions and cannot ship across state lines without meeting interstate distribution limits. A 503B outsourcing facility is registered with FDA, ships nationwide, and must comply with cGMP. You can search the FDA's outsourcing facility registry online. If the pharmacy claims 503B status, verify it. Ask where it sources bremelanotide. The pharmacy should name an FDA-registered API supplier or distributor and provide lot-specific certificates of analysis on request. If it says 'we get it from China' or 'it's research grade', walk away. Ask about sterility testing. Does the pharmacy follow USP 797? Does it perform media-fill validation? Does it test for endotoxin? A legitimate compounding facility will answer yes to all three and can provide documentation if your prescriber requests it. If the pharmacy says 'we use sterile technique' without naming a standard, that's insufficient. Ask about beyond-use dating. Injectable peptides are typically assigned 30-day beyond-use dates once reconstituted, or 90 to 180 days if lyophilized and stored frozen. If the pharmacy cannot tell you the beyond-use date or says 'it lasts as long as you keep it refrigerated', it's not following USP 795 or 797 dating rules. Finally, ask whether it reports adverse events. A pharmacy that participates in MedWatch and tracks patient outcomes is doing the right thing. A pharmacy that says 'we don't get involved after we ship' is not.

Why do research suppliers label products 'not for human use'?

The label is legal insulation. Under 21 CFR 201.128, a product's intended use is determined by labeling, advertising, and the circumstances of distribution ^[6]. If a vendor sells a chemical labeled 'for research only' to a laboratory that publishes scientific papers, FDA treats it as a research reagent, not a drug. If the same vendor sells the same chemical to individuals who clearly intend to inject it, the labeling is pretextual and FDA can prosecute for distributing an unapproved drug. Research suppliers know this. They include disclaimers in the product description ('This product is not for human or veterinary use. It is intended for research purposes only.'), require buyers to check a box agreeing they are not purchasing for personal use, and avoid any dosing or administration guidance on the website. Behind the scenes, they market heavily on bodybuilding forums, biohacking communities, and subreddits where users openly discuss injecting the peptides. The disclaimers are fig leaves. FDA has sent warning letters to research chemical vendors, particularly those selling SARMs and peptides with implied human-use marketing. These letters cite 21 U.S.C. 331(a) (introducing unapproved drugs into interstate commerce) and demand the vendor cease sales or relabel products. Some vendors shut down, rebrand, and reopen under a new domain. Others move operations offshore, shipping from Asia or Eastern Europe, which complicates enforcement but does not make the transaction legal for the buyer. From a buyer's perspective, the 'not for human use' label is a red flag, not a green light. It tells you the vendor is unwilling to stand behind the product's safety for the use you intend. It tells you the product is not manufactured or tested to pharmaceutical standards. And it tells you the vendor is structuring the transaction to avoid FDA oversight, which means you bear all the risk if something goes wrong.

What happens if I'm caught ordering from a research supplier?

If you order domestically, the risk is low but not zero. Domestic parcel services (USPS, UPS, FedEx) do not routinely inspect packages for research chemicals unless there's a tip-off or the sender is already under investigation. Most orders arrive without incident. If local law enforcement becomes aware (for example, if a vendor is busted and customer lists are seized), you might receive a warning letter or a knock-and-talk from a detective. Prosecution for personal-use quantities is rare but has happened in states with aggressive drug-enforcement policies. If you order internationally, Customs and Border Protection scans packages and can open suspicious shipments. Peptides often ship as white powder in small vials, which triggers scrutiny. If CBP identifies an unapproved drug, it issues a Notice of FDA Action, which is a polite letter saying the package was seized and offering you a chance to contest it. Most people do not contest. CBP destroys the package, and you're out the money. Repeated seizures can lead to further investigation, especially if you're ordering kilograms or reselling, but again, most personal-use buyers face no further consequence beyond losing the order. The bigger risk is medical. If you develop an infection, allergic reaction, or cardiovascular event and end up in an emergency room, the treating physician will ask what you took. If you say 'peptide I bought online', the hospital may report it as a poisoning or adverse drug event. That report goes to poison control and sometimes to the state health department. In rare cases, the health department investigates the supplier, and you might be contacted as a witness. You won't be prosecuted, but the incident becomes part of your medical record and could complicate future insurance underwriting or disability claims if the adverse event has lasting effects. For patients considering the legal, compounded route, see PT-141 peptide for men near me.

Does insurance cover compounded bremelanotide?

No. Compounded medications are generally excluded from insurance formularies because they lack FDA approval and NDC (National Drug Code) numbers that pharmacy benefit managers use to process claims. A few plans cover compounding for narrow indications (like hormone replacement in specific cancer patients), but sexual-function medications are almost universally carved out as non-covered lifestyle drugs. Vyleesi, the FDA-approved form, has an NDC and is theoretically covered, but most insurers place it in the highest tier with a $100-plus copay, and many require prior authorization. The prior authorization process demands documentation of failed first-line treatments, a psychiatric evaluation ruling out depression or relationship issues, and ongoing therapy. Approval rates are low. Even when approved, the copay is often so high that patients pay out of pocket anyway. Compounded bremelanotide from a 503B facility or a state-licensed pharmacy is cash-pay. The pharmacy provides an itemized receipt, and you can submit it to a health savings account (HSA) or flexible spending account (FSA) for reimbursement if your plan covers prescription medications. You cannot use a pharmacy discount card because compounded drugs are not in the card's network. And you cannot use manufacturer coupons because there is no manufacturer; the pharmacy is the manufacturer. Some telemedicine platforms that focus on sexual wellness charge a flat monthly or per-prescription fee that includes the consultation and the compound. That fee is not reimbursable by insurance, but it's transparent and often cheaper than trying to navigate insurance prior auth for Vyleesi. If you want to confirm your out-of-pocket cost before committing, see PT-141 and blood work for what tests might be recommended (and their costs).

Frequently asked questions

Can I legally buy PT-141 without a prescription?

No. Bremelanotide is a prescription-only medication. Research suppliers sell it labeled 'not for human use', which is a legal workaround that does not make the transaction lawful for you to inject. Possessing or using an unapproved drug violates federal law, even if the vendor ships it.

Is compounded bremelanotide the same quality as Vyleesi?

Not exactly. Vyleesi is manufactured under cGMP with full FDA oversight, batch testing, and stability data. Compounded bremelanotide from a 503B facility is also made under cGMP but may have shorter stability windows and less extensive testing. Compounded bremelanotide from a 503A pharmacy has even less oversight. All three are superior to research chemicals, which have zero regulatory oversight.

What purity should I expect from a research supplier?

COAs from research suppliers typically claim 95 to 99 percent purity by HPLC. These numbers reflect peptide content, not sterility or safety. Sterility, endotoxin, heavy metals, and residual solvents are not tested. Even if purity is high, the product may be unsafe to inject.

Do compounding pharmacies require a doctor visit?

They require a valid prescription, which means a provider must establish a patient relationship. Many telemedicine platforms offer virtual consultations, so you do not need an in-person visit. The consultation includes a health history, symptom review, and contraindication screening. If appropriate, the provider writes a prescription fulfilled by a partner compounding pharmacy.

Can I get bremelanotide compounded if I'm male?

Legally, yes, if your provider writes a prescription for off-label use and the pharmacy can compound it. Bremelanotide is FDA-approved only for premenopausal women with HSDD, but off-label prescribing is legal. Clinical trials in men have shown efficacy for erectile function and desire, though the data are less extensive than in women. For male-specific sourcing, see PT-141 peptide for men near me.

What should I do if my compounded bremelanotide causes a severe reaction?

Stop using it and seek medical care if you have difficulty breathing, chest pain, severe nausea, or signs of infection. Report the event to the pharmacy and your prescriber. The pharmacy should file a MedWatch report with FDA. If the reaction is serious, you may also file directly at fda.gov/medwatch. Save the vial and packaging so the pharmacy can investigate the batch.

Are there any legitimate research uses for PT-141?

Yes. Academic and pharmaceutical labs use bremelanotide in preclinical studies of melanocortin receptor pharmacology, sexual behavior in animal models, and metabolic signaling. Those labs buy from specialized chemical suppliers with proper documentation and do not inject the compounds into humans. A 'research supplier' selling to consumers is not serving legitimate research.

How long does compounded bremelanotide last once reconstituted?

Most compounding pharmacies assign a 30-day beyond-use date for reconstituted bremelanotide stored in a refrigerator. Lyophilized vials may be stable for 90 to 180 days if kept frozen and unopened. The beyond-use date is on the vial label and reflects stability data or USP default dating rules. Do not use the product past that date.

Can I travel internationally with compounded PT-141?

Traveling with any compounded medication is complicated. Customs authorities in other countries may not recognize US compounding pharmacy prescriptions, and peptides in vials can trigger scrutiny. Carry a copy of your prescription, a letter from your prescriber, and the pharmacy's contact information. Keep the medication in its original labeled vial. If you're going through Europe or Asia, check that country's import rules for personal medications; some require advance approval.

Do research suppliers ever get raided?

Yes. FDA and DEA have conducted enforcement actions against research chemical vendors, particularly those selling SARMs, peptides, and nootropics with clear human-use marketing. Operations are shut down, inventory seized, and operators sometimes face criminal charges. Customers rarely face prosecution, but customer lists can be subpoenaed if the investigation is large. The bigger consequence is that the vendor vanishes, and you lose any money paid for pending orders.

Is there a safer alternative to PT-141?

For hypoactive sexual desire disorder, the only other FDA-approved medication is flibanserin (Addyi), a daily oral pill that acts on serotonin receptors. It has its own side effect profile (sedation, low blood pressure) and cannot be taken with alcohol. Behavioral therapy, relationship counseling, and hormone optimization (testosterone in men, estrogen in postmenopausal women) are non-pharmacologic options. PT-141 is the only centrally acting on-demand option, which makes it unique but not necessarily safer. For women, see PT-141 in women.

What's the penalty for selling research PT-141 as a drug?

Under 21 U.S.C. 331, introducing an unapproved drug into interstate commerce is a federal offense. Penalties depend on intent and scale. Selling to friends or reselling research chemicals on forums can result in misdemeanor charges, fines up to $1,000, and a year in jail for a first offense. Operating a commercial distribution business without FDA approval is a felony, with fines and multi-year prison sentences. State laws vary, and some states add charges for practicing pharmacy without a license.

Can a veterinarian prescribe PT-141 for humans?

No. Veterinarians are licensed to prescribe for animals only. A veterinarian prescribing for a human is practicing medicine without a license, and a pharmacy filling that prescription is violating dispensing law. Some people try this workaround thinking vet prescriptions are less scrutinized, but state boards take it seriously, and both the vet and the pharmacy can lose their licenses.

Why don't all compounding pharmacies carry bremelanotide?

Because its legal status is murky. Bremelanotide is not on the current 503A bulks list, so most traditional compounding pharmacies avoid it to stay out of FDA's crosshairs. 503B outsourcing facilities have more flexibility and some do carry it, but they're fewer in number and more expensive to operate. Pharmacies that compound bremelanotide are making a judgment call about risk tolerance, and many prefer to wait until FDA formally adds it to the bulks list.

Sources

1. Drugs (PMID 31429064): Bremelanotide (Vyleesi) was approved by FDA in June 2019 for hypoactive sexual desire disorder in premenopausal women, delivered as 1.75 mg subcutaneous injection via autoinjector.
2. 21 U.S.C. 353a, pharmacy compounding: Section 503A of the FDCA permits pharmacies to compound drugs from bulk substances that appear on FDA's published list or meet nomination criteria, with restrictions on interstate distribution.
3. 21 CFR 216.23, the final 503A Bulks List: The current 503A bulk drug substances list, last updated July 2022, does not include bremelanotide.
4. 21 CFR 216.24, the 503B Bulks List: Outsourcing facilities (503B) may use bulk substances listed in 21 CFR 216.24, which is periodically updated and differs from the 503A list.
5. Federal Food, Drug, and Cosmetic Act: The FDCA prohibits introducing unapproved drugs into interstate commerce (21 U.S.C. 331(a)) and establishes the legal framework for FDA drug regulation.
6. 21 CFR 201.128, meaning of intended uses: A product's intended use is determined by labeling, advertising, and circumstances of distribution; labeling 'not for human use' does not shield a seller if the actual use is human injection.
7. FDA, bulk drug substances used in compounding under section 503A: FDA maintains a list of bulk substances that may be used in 503A compounding; substances not on the list may be nominated but are not compoundable until FDA adds them.
8. FDA, bulk drug substances nominated for use in compounding: FDA publishes a current list of nominated bulk substances under review for addition to the 503A list; nomination is a prerequisite but does not confer immediate compounding authority.
9. Obstetrics and Gynecology (PMID 31599840): Two Phase 3 trials (RECONNECT) demonstrated that bremelanotide 1.75 mg significantly improved desire and reduced distress in women with HSDD, with nausea and flushing as the most common side effects.
10. Journal of Women's Health (PMID 35147466): Integrated safety analysis across bremelanotide clinical trials found nausea (40%), flushing (20%), and injection-site reactions (13%) as the most frequent adverse events; no serious cardiovascular events were attributed to the drug.
11. CNS Spectrums (PMID 33455598): Bremelanotide acts as an agonist at melanocortin MC3R and MC4R receptors in the central nervous system, modulating neural circuits involved in sexual motivation and arousal.
12. Journal of Sex Research (PMID 36809187): A reanalysis of RECONNECT trial data found small absolute effect sizes for bremelanotide on desire and satisfaction domains, with questionable clinical significance and high placebo response rates.